Various mouse models have been developed and widely exploited in cancer research. To evaluate the efficacy of cancer treatments in preclinical and clinical studies, human tumor xenograft models whereby human cell lines are transplanted into immunocompromized mice are commonly used. In particular, orthotopically implantation of human tumor cells into the equivalent mouse organ where cancer originated is preferred for demonstrating the effects of new cancer drugs on specific tumors because it provides tumor cells a microenvironment for organotypic interaction which may affect tumor growth, differentiation, and its response to drugs. Orthotopic tumor models offer more clinical relevance for tissue site-specific pathology and hence provide prospective evaluation for chemotherapeutic drugs.
With superior skills, Abnova has successfully established several orthotopic human tumor models for researchers to evaluate the in vivo efficacy of new compounds for cancer therapy, and more orthotopic models for 8 most common human cancers are in development. With a luciferase-expressing cell line directly injected into the relevant organ of a live mouse, the orthotopically implanted tumor cells can be easily detected and the growth of tumor in response to anticancer compounds can be monitored in vivo with the IVISR biophotonic imaging system. Besides providing orthotopic mouse models for different cancers, we also offer customized drug injection services for the convenience of our customers.
|
|
|
|
|
|
|
|
|
|
|
|
Luciferase expression from the orthotopic liver tumor in anesthetized NOD/SCID mice (stable cell line used: HepG2-Luc) |
|
Luciferase expression from the orthotopic lung tumor in anesthetized NOD/SCID mice (stable cell line used: A549-Luc) |
|
|
|
|
|
H&E stain showing colorectal cancer liver metastatic lesions 7 days post-intrasplenic injection in BALB/c mice of CT26 syngeneic murine model. | |
Tumor volume of the liver cancer BNL 1ME A.7R.1 syngeneic murine model was measured 14 days post tumor cell implantation. The tumor-bearing mice were divided into two groups, non-treated and treated groups. The treated group was intravenously injected with the anti-tumor drug and the non-treated group received PBS. Mice were sacrificed 14 days post-treatment. (A) The results showed that tumor weight was significantly decreased in the treated group compared to the non-treated group. (B) Images of the tumor on the liver were shown before treatment (Day 0) and 14 days post-treatment. | |
- oem@abnova.com
- TW : +886-2-8751-1888 / USA : +1(857) 639 0367 / Korea : +82-1670-5911.